Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.

[1]  A. Dick,et al.  Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. , 2018, Ophthalmology.

[2]  A. Denniston,et al.  Uveitis: a sight-threatening disease which can impact all systems , 2017, Postgraduate Medical Journal.

[3]  M. Galeazzi,et al.  Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. , 2017, The Israel Medical Association journal : IMAJ.

[4]  Matthieu Defrance,et al.  MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis , 2017, Journal of Neuroinflammation.

[5]  S. Srivastava,et al.  Association Between Visual Function Response and Reduction of Inflammation in Noninfectious Uveitis of the Posterior Segment. , 2017, Investigative ophthalmology & visual science.

[6]  Jia Liu,et al.  Intravitreal infusion: A novel approach for intraocular drug delivery , 2016, Scientific Reports.

[7]  Q. Nguyen,et al.  Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). , 2016, Ophthalmology.

[8]  Cecilia S Lee,et al.  Management of noninfectious posterior uveitis with intravitreal drug therapy , 2016, Clinical ophthalmology.

[9]  A. Dick,et al.  Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial , 2016, The Lancet.

[10]  A. Heiligenhaus,et al.  Adalimumab in Patients with Active Noninfectious Uveitis. , 2016, The New England journal of medicine.

[11]  Q. Nguyen,et al.  The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis). , 2016, Transactions of the American Ophthalmological Society.

[12]  A. Dick,et al.  Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis , 2016, Acta ophthalmologica.

[13]  Michael N. Hall,et al.  Architecture of human mTOR complex 1 , 2016, Science.

[14]  E. Cunningham,et al.  Sustained-release Corticosteroids for Uveitis , 2015, Ocular immunology and inflammation.

[15]  A. Urtti,et al.  Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data. , 2015, Experimental eye research.

[16]  J. Kempen,et al.  Prevalence and Risk Factors of Epiretinal membrane in the Multicenter Uveitis Steroid Treatment (MUST) Trial , 2015 .

[17]  N. Jones.  The Manchester Uveitis Clinic: The First 3000 Patients—Epidemiology and Casemix , 2015, Ocular immunology and inflammation.

[18]  N. Jones.  The Manchester Uveitis Clinic: The first 3000 patients, 2: Uveitis Manifestations, Complications, Medical and Surgical Management , 2015, Ocular immunology and inflammation.

[19]  Q. Nguyen,et al.  One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis. , 2015, Translational vision science & technology.

[20]  A. Dick,et al.  Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. , 2014, American journal of ophthalmology.

[21]  A. Bar,et al.  Long-term clinical outcome and causes of vision loss in patients with uveitis. , 2014, Ophthalmology.

[22]  George A. Williams,et al.  INTRAVITREAL INJECTION TECHNIQUE AND MONITORING: Updated Guidelines of an Expert Panel , 2014, Retina.

[23]  A. Dick,et al.  Autoimmune and autoinflammatory mechanisms in uveitis , 2014, Seminars in Immunopathology.

[24]  J. Rosenbaum,et al.  Update on the use of systemic biologic agents in the treatment of noninfectious uveitis , 2014, Biologics : targets & therapy.

[25]  D. Chu,et al.  Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA , 2013, Journal of Ophthalmic Inflammation and Infection.

[26]  Jacques P. Brown,et al.  A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy , 2013, Allergy, Asthma & Clinical Immunology.

[27]  F. Bandello,et al.  Review on the Worldwide Epidemiology of Uveitis , 2013, European journal of ophthalmology.

[28]  J. Naor,et al.  Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study , 2013, Journal of Ophthalmic Inflammation and Infection.

[29]  J. Naor,et al.  Tolerability and pharmacokinetics of intravitreal sirolimus. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[30]  Hongbo Chi,et al.  Regulation and function of mTOR signalling in T cell fate decisions , 2012, Nature Reviews Immunology.

[31]  M. Horton,et al.  Regulation of immune responses by mTOR. , 2012, Annual review of immunology.

[32]  A. Dick,et al.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis , 2012, Progress in Retinal and Eye Research.

[33]  J. Vander.  Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial , 2012 .

[34]  George A. Williams,et al.  A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. , 2012, Ophthalmology.

[35]  P. Murray,et al.  Understanding uveitis: The impact of research on visual outcomes , 2011, Progress in Retinal and Eye Research.

[36]  T. Louis,et al.  Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. , 2011, Ophthalmology.

[37]  C. Lowder,et al.  Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. , 2011, Archives of ophthalmology.

[38]  P. Worley,et al.  The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling , 2011, Nature Immunology.

[39]  W. Feuer,et al.  Scale for photographic grading of vitreous haze in uveitis. , 2010, American journal of ophthalmology.

[40]  R. Caspi.  A look at autoimmunity and inflammation in the eye. , 2010, The Journal of clinical investigation.

[41]  P. Chévez-Barrios,et al.  Testing intravitreal toxicity of rapamycin in rabbit eyes. , 2009, Arquivos brasileiros de oftalmologia.

[42]  B. Gilger,et al.  Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. , 2008, Journal of veterinary pharmacology and therapeutics.

[43]  Q. Nguyen,et al.  Treating Chronic Noninfectious Posterior Segment Uveitis: The Impact of Cumulative Damage Proceedings of an Expert Panel Roundtable Discussion , 2006, Retina.

[44]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[45]  H. Dua,et al.  The efficacy of sirolimus in the treatment of patients with refractory uveitis , 2005, British Journal of Ophthalmology.

[46]  Andrew D. Dick,et al.  The standardization of uveitis nomenclature (SUN) working group; standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop , 2005 .

[47]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[48]  P. Taylor,et al.  From Beach to Bedside: History of the Development of Sirolimus , 2001, Therapeutic drug monitoring.

[49]  S. Yalkowsky,et al.  Solubilization of rapamycin. , 2001, International journal of pharmaceutics.

[50]  M. Metcalfe,et al.  Rapamycin in transplantation: a review of the evidence. , 2001, Kidney international.

[51]  R. V. Van Gelder,et al.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. , 2000, American journal of ophthalmology.

[52]  V. Berlin,et al.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Chan,et al.  Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. , 1993, Current eye research.

[54]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[55]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.